About
UNITE4TB concept
To address the challenge of developing new TB treatment regimens, UNITE4TB follows a concept that is analogous to a car racetrack.
Through its EFPIA and Associated Partners UNITE4TB ensures access to the majority of the most innovative TB compounds. These compounds, the key car parts, will enter the pitstop when they are phase 2-ready and be incorporated into a new treatment regimen (the race car).
Potential combination regimens will then be launched onto the racetrack (a clinical trial platform with 40 trial sites on four continents) to participate in the race to select the best car or treatment regimen.
New car parts (drugs) and cars (regimens) may enter the race when ready, making this a state-of-the-art adaptive trial design with conventional and new biomarkers of treatment success. Advanced pharmacokinetic and pharmacodynamic modelling techniques and artificial intelligence and machine learning techniques will be employed to select, test and deliver novel combination regimens with a high probability of success in subsequent phase 3 clinical trials.